Shilpa Medicare Q2 FY25 consolidated PAT up 1,008% at Rs. 18 Cr

Suven Pharmaceuticals Q2 FY25 revenue grows 12% in Q2

Pharma CDMO business has posted a 40% YoY in Q2 driven by BD efforts and backed by macro tailwinds

EMA grants GMP Certificate of compliance to CuraTeQ biosimilars’ Hyderabad facility

The GMP inspection assessed mammalian and microbial drug substance manufacturing facility sections

Hikal Q2 FY25 revenue stood at Rs. 453 Cr

In Q2 FY25, our crop protection segment reported revenue of Rs. 159 crore, with an EBIT margin of 5%

Akums Drugs and Pharmaceuticals posts Q2 FY25 adjusted PAT at Rs. 66.7 Cr

For Q2, Akums reported a consolidated total income of Rs. 1,046.6 crore

USFDA classifies Biocon Biologics’ Biocon Park in Bengaluru as VAI

The inspection scope had included six separate Biologics manufacturing units comprising of four Drug Substance and two Drug Product manufacturing plants

Orchid Pharma Q2 FY25 PAT up 26% YoY driven by strategic initiatives for market expansion

Granules India’s Unit V facility secures USFDA EIR with NAI status

The FDA conducted a comprehensive Pre-Approval Inspection (PAI) and cGMP audit

Henkel, Covestro and Quad Industries collaborate for advanced medical wearables based on printed electronics

Combined capabilities to drive novel healthcare applications presented at MEDICA 2024

Lupin receives tentative approval from USFDA for Raltegravir Tablets

This product will be manufactured at Lupin’s Nagpur facility in India